ライフサイエンスコーパス: rabbit antithymocyte globulin

1 nventional induction therapy (basiliximab or rabbit antithymocyte globulin).

2 bortezomib, methylprednisone, rituximab, and rabbit antithymocyte globulin.

3 and either 20 mg alemtuzumab or 6 mg per kg rabbit antithymocyte globulin.

4 lymphoid irradiation, cyclophosphamide, and rabbit-antithymocyte globulin.

5 after successful induction therapy using two rabbit antithymocyte globulins.

6 one were randomly assigned to receive either rabbit antithymocyte globulin (1.5 mg per kilogram of bo

7 difference was seen between alemtuzumab and rabbit antithymocyte globulin (18% vs. 15%, P=0.63).

8 no donor-specific antibodies [DSA]) received rabbit antithymocyte globulin (2 x 1.5 mg/kg, postoperat

9 zumab (one dose of 30 mg, in 70 patients) or rabbit antithymocyte globulin (a total of 6 mg per kilog

10 imed at assessing the efficacy and safety of rabbit antithymocyte globulin and infliximab induction i

11 plant recipients who received induction with rabbit antithymocyte globulin and rituximab and initiate

12 nonmyeloablative conditioning protocol with rabbit-antithymocyte globulin and low-dose total lymphoi

13 Eighty-two patients received rabbit antithymocyte globulin (ATG) as part of the condi

14 The addition of low, nondepleting doses of rabbit antithymocyte globulin (ATG) to human peripheral

15 transplant total lymphoid irradiation (TLI), rabbit antithymocyte globulin (ATG), and a single donor

16 and 2022 and compared the risk of PTLD with rabbit antithymocyte globulin (ATG), basiliximab, and al

17 Polyclonal rabbit antithymocyte globulins (ATGs) are commonly used

18 poside, cytarabine, and melphalan as well as rabbit antithymocyte globulin before autologous HCT.

19 ey transplant recipients who were prescribed rabbit antithymocyte globulin, calcineurin inhibitor, my

20 steroid elimination at 1 week, and combined rabbit antithymocyte globulin/daclizumab induction, prev

21 ts suggests that the use of a single 3 mg/kg rabbit antithymocyte globulin dose followed by EVR combi

22 ted with about 5 mg/kg of a broadly reacting rabbit antithymocyte globulin during several hours.

23 acrolimus, everolimus (EVR), and prednisone (rabbit antithymocyte globulin/EVR, n = 85); basiliximab,

24 Rabbit antithymocyte globulin facilitates apoptosis of a

25 We therefore tested T-cell depletion with rabbit antithymocyte globulin followed by sirolimus mono

26 All participants were treated with rabbit antithymocyte globulin for induction immunosuppre

27 phylactic CMVIG and induction with high-dose rabbit antithymocyte globulin (>10 mg/kg) were associate

28 n; among high-risk patients, alemtuzumab and rabbit antithymocyte globulin had similar efficacy.

29 ts required steroid therapy and one required rabbit antithymocyte globulin in addition to MMF and ste

30 80-day mortality among patients who received rabbit antithymocyte globulin induction (P = .001).

31 on maintenance prednisone in the setting of rabbit antithymocyte globulin induction and tacrolimus a

32 der-drained PAK (n=47) transplants receiving rabbit antithymocyte globulin induction from June 1998 t

33 n early corticosteroid withdrawal regimen of rabbit antithymocyte globulin induction, tacrolimus, and

34 n early corticosteroid withdrawal regimen of rabbit antithymocyte globulin induction, tacrolimus, myc

35 with cyclosporine and corticosteroids after rabbit antithymocyte globulin induction.

36 The patient received methylprednisolone and rabbit antithymocyte globulin intravenously during scalp

37 Induction therapy with rabbit antithymocyte globulin may achieve a short-term d

38 is with CMVIG and appropriate induction with rabbit antithymocyte globulin may be important to reduce

39 recipient pretreatment with a single dose of rabbit antithymocyte globulin or alemtuzumab and posttra

40 late mofetil were required as well as either rabbit antithymocyte globulin or interleukin-2 receptor

41 ain immunosuppressive regimens that included rabbit antithymocyte globulin or tacrolimus/mycophenolat

42 cyclophosphamide, and 6.5 mg/kg intravenous rabbit antithymocyte globulin or to receive 1.0 g/m(2) i

43 alemtuzumab (versus no induction, anti-CD25, rabbit antithymocyte globulin, or rabbit antithymocyte g

44 ction categories: no-induction, alemtuzumab, rabbit antithymocyte globulin (r-ATG), and interleukin-2

45 ne were randomized for 3 different regimens: rabbit antithymocyte globulin (r-ATG)/EVR (N = 85); basi

46 Recipients were grouped by induction type: rabbit antithymocyte globulin (r-ATG, n = 688) and human

47 to December 2008 who received induction with rabbit-antithymocyte globulin (r-ATG), alemtuzumab, or a

48 stics, we generated 1:1 pairs of alemtuzumab-rabbit antithymocyte globulin (rATG) (5330 pairs) and ba

49 Patients were treated with T cell-depleting rabbit antithymocyte globulin (rATG) (6 mg/kg, n = 17) o

50 when alemtuzumab induction was compared with rabbit antithymocyte globulin (rATG) (Thymoglobulin [Gen

51 ing strategies have not been established for rabbit antithymocyte globulin (rATG) after heart transpl

52 Rabbit antithymocyte globulin (rATG) and horse ATG (hATG

53 Treatment using induction therapy with rabbit antithymocyte globulin (RATG) and intravenous imm

54 Alemtuzumab and rabbit antithymocyte globulin (rATG) are commonly used f

55 Despite the prevalent use of rabbit antithymocyte globulin (rATG) as an induction age

56 ne the safety and efficacy of induction with rabbit antithymocyte globulin (RATG) compared with inter

57 Rabbit antithymocyte globulin (rATG) effectively deplete

58 We evaluated the use of rabbit antithymocyte globulin (rATG) for corticosteroid

59 71 patients who received either steroids or rabbit antithymocyte globulin (RATG) for orthotopic live

60 adult recipients who received rituximab and rabbit antithymocyte globulin (rATG) in combination as i

61 teroid-free immunosuppression protocol using rabbit antithymocyte globulin (RATG) induction in orthot

62 Rabbit antithymocyte globulin (rATG) induction is associ

63 Optimal dosing of rabbit antithymocyte globulin (rATG) induction therapy i

64 discharge, we developed a protocol to extend rabbit antithymocyte globulin (rATG) induction therapy i

65 imus 1.5 mg versus MMF in patients receiving rabbit antithymocyte globulin (rATG) induction, mainly d

66 nt centers comparing a control group of with rabbit antithymocyte globulin (rATG) induction, rapid st

67 Induction rabbit antithymocyte globulin (rATG) is largely used in

68 Delaying CNI initiation by using induction rabbit antithymocyte globulin (rATG) may provide kidneys

69 ients, who were randomized to receive either rabbit antithymocyte globulin (RATG) or steroids as indu

70 bsets were evaluated before and after adding rabbit antithymocyte globulin (rATG) to mixed lymphocyte

71 mparing single-dose (SD) versus divided-dose rabbit antithymocyte globulin (rATG), and a maintenance

72 Thymoglobulin, rabbit antithymocyte globulin (RATG), has been shown to

73 ace, human leukocyte antigen (HLA) mismatch, rabbit antithymocyte globulin (RATG), interleukin-2 rece

74 ostatic proliferation by Ki-67(+) T cells in rabbit antithymocyte globulin (rATG)-treated patients th

75 ved combined therapy with PPH and polyclonal rabbit antithymocyte globulin (rATG).

76 tients exposed (4.23%) versus not exposed to rabbit antithymocyte globulin (rATG; 0.53%; P=0.019) or

77 n basiliximab (1998), daclizumab (1998), and rabbit antithymocyte globulin (rATG; 1999) replaced anti

78 the prognostic influence of induction type: rabbit antithymocyte globulin (rATG; 2 mg/kg x 5)/rituxi

79 tablished to assess clinical experience with rabbit antithymocyte globulin (rATG; Thymoglobulin) in l

80 Rabbit antithymocyte globulin (rATG; thymoglobulin, Genz

81 e thousand consecutive LT patients receiving rabbit antithymocyte globulin+/-rituximab induction were

82 With the use of rabbit antithymocyte globulin+/-rituximab induction, ove

83 anti-CD25, rabbit antithymocyte globulin, or rabbit antithymocyte globulin/rituximab) induction (P =

84 nosuppression was Tac-Pred based in nine and rabbit antithymocyte globulin-Tac based in six cases.

85 e-ITx was carried out under Tac-Pred in six, rabbit antithymocyte globulin-Tac in eight, and alemtuzu

86 ndomized to receive a single 3-mg/kg dose of rabbit antithymocyte globulin, tacrolimus, everolimus (E

87 Subjects received rabbit antithymocyte globulin, tacrolimus, mycophenolate

88 d pretreatment with approximately 5 mg/kg of rabbit antithymocyte globulin (Thymoglobulin) in the hou

89 a randomized, international study comparing rabbit antithymocyte globulin (TMG) and basiliximab (BAS

90 tients with Aspergillus colonization, use of rabbit antithymocyte globulin was associated with 4-fold

91 lation using busulfan, cyclophosphamide, and rabbit antithymocyte globulin was followed by aHSCT.

92 ox-proportional hazard model, treatment with rabbit antithymocyte globulin was significantly associat